News
Aurobindo Pharma receives final approval for Divalproex Sodium Delayed-Release Tablets
Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration to manufacture and market Divalproex Sodium Delayed - Release Tablets USP 125mg, 250mg and 500mg. ...
News
Thermo Fisher Scientific Introduces New Cell Assay for Predictive Liver Toxicity Testing
Thermo Fisher Scientific Inc., the world leader in serving science has introduced the ToxInsight DILI Assay Cartridge, a groundbreaking new tool for assessing the liver toxicity risk of chemical compounds. It will help pharmaceutical companies improve their productivity by...
News
Novartis completes merger with Alcon
Novartis announced that it completed the merger of Alcon, Inc. Â into Novartis. The completion of the merger follows the Novartis shareholders' approval of the merger, as well as the proposed capital increase at the company's Extraordinary Shareholder Meeting...
News
NextPharma Announces the Addition of a New Encapsulation/Over-encapsulation Machine
NextPharma the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotech industry, is pleased to announce that it has enhanced its Clinical Trials Services (CTS)  facility in Göttingen,...
News
Thermo Fisher Scientific Completes Sales of Athena Diagnostics and Lancaster Laboratories
Thermo Fisher Scientific Inc., the world leader in serving science, has completed the previously announced sales of its two laboratory-testing services businesses, Athena Diagnostics and Lancaster Laboratories, in two separate transactions, resulting in total proceeds of $940 million....
News
Nycomed announces REACT study to evaluate impact of Daxas
Nycomed announced plans for an international phase III/IV study investigating the effect of Daxas® (500μg tablets, once daily) versus placebo on exacerbation rates in COPD patients who are concomitantly treated with fixed combination long-acting-ß2-agonists (LABA) and inhaled corticosteroids (ICS),...
News
APP Pharmaceuticals issues nationwide voluntary recall of Irinotecan Hydrochloride Injection
APP Pharmaceuticals, Inc., announced that it has issued a voluntary recall of five lots of Irinotecan Hydrochloride Injection, which is used for recurrent or progressive metastatic colorectal cancer. This recall is being conducted as a precautionary measure and there...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
